TY - JOUR
T1 - Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities
AU - Goveia, Jermaine
AU - Pircher, Andreas
AU - Conradi, Lena Christin
AU - Kalucka, Joanna
AU - Lagani, Vincenzo
AU - Dewerchin, Mieke
AU - Eelen, Guy
AU - DeBerardinis, Ralph J.
AU - Wilson, Ian D.
AU - Carmeliet, Peter
N1 - Generated from Scopus record by KAUST IRTS on 2023-09-23
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Cancer cell metabolism has received increasing attention. Despite a boost in the application of clinical metabolic profiling (CMP) in cancer patients, a meta-analysis has not been performed. The primary goal of this study was to assess whether public accessibility of metabolomics data and identification and reporting of metabolites were sufficient to assess which metabolites were consistently altered in cancer patients. We therefore retrospectively curated data from CMP studies in cancer patients published during 5 recent years and used an established vote-counting method to perform a semiquantitative meta-analysis of metabolites in tumor tissue and blood. This analysis confirmed well-known increases in glycolytic metabolites, but also unveiled unprecedented changes in other metabolites such as ketone bodies and amino acids (histidine, tryptophan). However, this study also highlighted that insufficient public accessibility of metabolomics data, and inadequate metabolite identification and reporting hamper the discovery potential of meta-analyses of CMP studies, calling for improved standardization of metabolomics studies.
AB - Cancer cell metabolism has received increasing attention. Despite a boost in the application of clinical metabolic profiling (CMP) in cancer patients, a meta-analysis has not been performed. The primary goal of this study was to assess whether public accessibility of metabolomics data and identification and reporting of metabolites were sufficient to assess which metabolites were consistently altered in cancer patients. We therefore retrospectively curated data from CMP studies in cancer patients published during 5 recent years and used an established vote-counting method to perform a semiquantitative meta-analysis of metabolites in tumor tissue and blood. This analysis confirmed well-known increases in glycolytic metabolites, but also unveiled unprecedented changes in other metabolites such as ketone bodies and amino acids (histidine, tryptophan). However, this study also highlighted that insufficient public accessibility of metabolomics data, and inadequate metabolite identification and reporting hamper the discovery potential of meta-analyses of CMP studies, calling for improved standardization of metabolomics studies.
UR - https://www.embopress.org/doi/10.15252/emmm.201606798
UR - http://www.scopus.com/inward/record.url?scp=84989959246&partnerID=8YFLogxK
U2 - 10.15252/emmm.201606798
DO - 10.15252/emmm.201606798
M3 - Article
SN - 1757-4684
VL - 8
SP - 1134
EP - 1142
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 10
ER -